Principal causal effect identification and surrogate end point evaluation by multiple trials

被引:16
|
作者
Jiang, Zhichao [1 ]
Ding, Peng [2 ]
Geng, Zhi [1 ]
机构
[1] Peking Univ, Beijing, Peoples R China
[2] Univ Calif Berkeley, Berkeley, CA 94720 USA
基金
中国国家自然科学基金;
关键词
Causal inference; Causal necessity; Causal sufficiency; Clinical trial; Criterion for surrogate end points; POTENTIAL OUTCOMES; AUGMENTED DESIGNS; VACCINE TRIALS; STRATIFICATION; INFERENCE; NONCOMPLIANCE; CRITERIA; MODELS; DEATH; DISTRIBUTIONS;
D O I
10.1111/rssb.12135
中图分类号
O21 [概率论与数理统计]; C8 [统计学];
学科分类号
020208 ; 070103 ; 0714 ;
摘要
Principal stratification is a causal framework to analyse randomized experiments with a post-treatment variable between the treatment and end point variables. Because the principal strata defined by the potential outcomes of the post-treatment variable are not observable, we generally cannot identify the causal effects within principal strata. Motivated by a real data set of phase III adjuvant colon cancer clinical trials, we propose approaches to identifying and estimating the principal causal effects via multiple trials. For the identifiability, we remove the commonly used exclusion restriction assumption by stipulating that the principal causal effects are homogeneous across these trials. To remove another commonly used monotonicity assumption, we give a necessary condition for the local identifiability, which requires at least three trials. Applying our approaches to the data from adjuvant colon cancer clinical trials, we find that the commonly used monotonicity assumption is untenable, and disease-free survival with 3-year follow-up is a valid surrogate end point for overall survival with 5-year follow-up, which satisfies both causal necessity and causal sufficiency. We also propose a sensitivity analysis approach based on Bayesian hierarchical models to investigate the effect of the deviation from the homogeneity assumption.
引用
收藏
页码:829 / 848
页数:20
相关论文
共 50 条
  • [1] Arterial Stiffness as Surrogate End Point Needed Clinical Trials
    Laurent, Stephane
    Briet, Marie
    Boutouyrie, Pierre
    HYPERTENSION, 2012, 60 (02) : 518 - 522
  • [2] Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy
    Thompson, Aliza
    Carroll, Kevin
    Inker, Lesley A.
    Floege, Jurgen
    Perkovic, Vlado
    Boyer-Suavet, Sonia
    Major, Rupert W.
    Schimpf, Judith, I
    Barratt, Jonathan
    Cattran, Daniel C.
    Gillespie, Barbara S.
    Kausz, Annamaria
    Mercer, Alex W.
    Reich, Heather N.
    Rovin, Brad H.
    West, Melissa
    Nachman, Patrick H.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2019, 14 (03): : 469 - 481
  • [3] CHEMOPREVENTION TRIALS AND SURROGATE END-POINT BIOMARKERS IN THE CERVIX
    MITCHELL, MF
    HITTELMAN, WK
    LOTAN, R
    NISHIOKA, K
    TORTOLEROLUNA, G
    RICHARDSKORTUM, R
    WHARTON, JT
    HONG, WK
    CANCER, 1995, 76 (10) : 1956 - 1977
  • [4] SURROGATE END-POINT USE IN CARDIOVASCULAR CLINICAL-TRIALS
    PROBSTFIELD, JL
    YUSUF, S
    FRIEDMAN, LM
    LABARTHE, DR
    BRISTOW, JD
    WITTES, J
    CONTROLLED CLINICAL TRIALS, 1986, 7 (03): : 241 - 242
  • [5] Surrogate end point fallacies -: The urge for randomized trials with clinical endpoints
    Muehlhauser, Ingrid
    Meyer, Gabriele
    PSYCHOTHERAPIE PSYCHOSOMATIK MEDIZINISCHE PSYCHOLOGIE, 2006, 56 (05) : 193 - 201
  • [6] Protein C as a surrogate end-point for clinical trials of sepsis
    Liu, Kathleen D.
    Matthay, Michael A.
    CRITICAL CARE, 2008, 12 (02):
  • [7] PFS as a surrogate end point for OS in advanced colorectal cancer trials
    Nature Clinical Practice Oncology, 2008, 5 (5): : 245 - 245
  • [8] What Constitutes a Valid Surrogate End Point in Cancer Clinical Trials?
    Shyr, Yu
    Shyr, Derek
    JAMA ONCOLOGY, 2020, 6 (09) : 1334 - 1335
  • [9] Protein C as a surrogate end-point for clinical trials of sepsis
    Kathleen D Liu
    Michael A Matthay
    Critical Care, 12
  • [10] A Bayesian Approach to Improved Estimation of Causal Effect Predictiveness for a Principal Surrogate Endpoint
    Zigler, Corwin M.
    Belin, Thomas R.
    BIOMETRICS, 2012, 68 (03) : 922 - 932